• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Allergan wins round in patent fight over Lumigan

Article

Appeals court upheld a decision favoring Allergan in a patent contest against two generic drug makers over the drug Lumigan.

Washington, DC-Allergan won a round in a patent fight against two generic drug makers when an appeals court found a key portion of the patent for its glaucoma drug Lumigan was valid.

The U.S. Court of Appeals for the Federal Circuit also ruled that Sandoz Inc., the generic unit of Novartis AG, and Barr Laboratories Inc., a business unit of Teva Pharmaceuticals, would infringe that patent if they went through with plans to sell a generic version of Lumigan. The appeals court upheld a decision from the U.S. Court of Appeals for the District of Delaware.

Allergan’s Lumigan has annual sales of more than $600 million.

The case is at the U.S. Court of Appeals for the Federal Circuit. It is Allergan Inc. v. Barr Laboratories, Teva Pharmaceuticals, and Sandoz Inc. The case numbers are 2012-1040, 2012-1054.

Related Videos
R Tracy Williams, OD, FAAO, details his experience as a sports team optometrist
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
© 2024 MJH Life Sciences

All rights reserved.